April Expo 2023: iQure Pharma

iQure Pharma develops therapeutic candidates with novel mechanisms of action for the treatment of epilepsy and neuropathic pain. iQ-007 shows outstanding results in preclinical drug-resistant epilepsy models. iQ-008 is a breakthrough multitargeting compound with efficacy superior to Pregabalin (Lyrica, Pfizer). iQ-007 successfully completed the NIH Epilepsy screening program and iQ-008 completed Tier 1 NIH Pain screening program.

Get access to the iQure Pharma Deal: https://app.dealum.com/#/company/publicprofile/39808/1wrkklmpnhmumtev8xy6x0itr5n5pz81